[A case report. Rosiglitazone treatment was highly effective yet had to be terminated].
The thiazolidinediones were introduced as oral hypoglycemic drugs in Sweden during the fall of 2000. A case is reported in which a woman with insulin-dependent type-2 diabetes and both macro- and microangiopathy and pronounced insulin resistance was treated with rosiglitazone (Avandia). Within three months insulin doses could be reduced by 36% (from 176 to 112 units insulin daily) and concomitantly Ery-HbA1c was reduced from 8.4 to 5.3%. In spite of this dramatic effect on glucose homeostasis administration of the drug had to be discontinued due to critical congestive heart failure.
Ridderstråle
Martin
M
Endokrinologiska kliniken, Universitetssjukhuset MAS, Malmö. martin.ridderstrale@endo.mas.lu.se
Groop
Leif
L
D000284:Administration, Oral; D000075202:Contraindications; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000187:drug effects; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage; D007328:Insulin / Q000627:therapeutic use; D008875:Middle Aged; D000077154:Rosiglitazone; D013844:Thiazoles / Q000008:administration & dosage; D045162:Thiazolidinediones; D016896:Treatment Outcome
D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000077154:Rosiglitazone; D013844:Thiazoles; D045162:Thiazolidinediones